Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126420671 | 12642067 | 1 | I | 20160606 | 20160726 | 20160810 | 20160810 | EXP | IT-VALIDUS PHARMACEUTICALS LLC-IT-2016VAL002401 | VALIDUS | 87.00 | YR | F | Y | 0.00000 | 20160810 | MD | IT | IT |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126420671 | 12642067 | 1 | PS | FUROSEMIDE. | FUROSEMIDE | 1 | Oral | 125 MG, DAILY | 16273 | 125 | MG | TABLET | |||||||
| 126420671 | 12642067 | 2 | C | ASCRIPTIN | ASPIRIN | 1 | UNK | U | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126420671 | 12642067 | 1 | Gravitational oedema |
| 126420671 | 12642067 | 2 | Product used for unknown indication |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126420671 | 12642067 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126420671 | 12642067 | Acute kidney injury | |
| 126420671 | 12642067 | Asthenia | |
| 126420671 | 12642067 | Hypokalaemia | |
| 126420671 | 12642067 | Metabolic alkalosis |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 126420671 | 12642067 | 1 | 20160501 | 20160606 | 0 |